Reuters logo
EU follows U.S. lead in studying diabetes drugs risks
March 26, 2013 / 3:20 PM / 5 years ago

EU follows U.S. lead in studying diabetes drugs risks

LONDON, March 26 (Reuters) - The European Medicines Agency said on Tuesday it was investigating the possibility that two widely used classes of diabetes drugs might cause inflammation of the pancreas and pre-cancerous changes.

The decision to study so-called GLP-1 therapies and DPP-4 drugs follows similar action earlier this month by the U.S. Food and Drug Administration.

Drugs affected include Novo Nordisk’s Victoza, Merck & Co’s Januvia, and Onglyza from Bristol-Myers Squibb and AstraZeneca.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below